| 2025-12-01 |
详情>>
内部人交易：
Viehbacher Christopher共交易2笔
|
| 2025-10-30 |
详情>>
股本变动：
变动后总股本14670.23万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益9.16美元,归母净利润13.42亿美元,同比去年增长-1.74%
|
| 2025-10-30 |
财报披露：
美东时间 2025-10-30 盘前发布财报
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益5.98美元,归母净利润8.75亿美元,同比去年增长-10.41%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益1.65美元,归母净利润2.40亿美元,同比去年增长-38.87%
|
| 2025-04-28 |
股东大会：
将于2025-06-17召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees identified in the accompanying Proxy Statement to our Board to each serve for a one-year term extending until our 2026 annual meeting of stockholders and his or her successor is duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
3.To hold an advisory vote on executive compensation.
4.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2025-02-12 |
详情>>
业绩披露：
2024年年报每股收益11.21美元,归母净利润16.32亿美元,同比去年增长40.57%
|
| 2025-02-12 |
详情>>
业绩披露：
2022年年报每股收益20.96美元,归母净利润30.47亿美元,同比去年增长95.80%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益9.38美元,归母净利润13.65亿美元,同比去年增长49.82%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益6.72美元,归母净利润9.77亿美元,同比去年增长-0.26%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益6.78美元,归母净利润9.79亿美元,同比去年增长-28.07%
|
| 2024-04-26 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.To elect the 9 nominees identified in the accompanying Proxy Statement to our Board to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP (PwC) as our independent registered public accounting firm for fiscal year ending December 31, 2024.
3.To hold an advisory vote on executive compensation.
4.To approve an amendment to Biogen’s Amended and Restated Certificate of Incorporation, as amended, to add an officer exculpation provision.
5.To approve the Biogen Inc. 2024 Omnibus Plan.
6.To approve the Biogen Inc. 2024 Employee Stock Purchase Plan.
7.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2024-04-24 |
详情>>
业绩披露：
2024年一季报每股收益2.71美元,归母净利润3.93亿美元,同比去年增长1.42%
|
| 2024-02-14 |
详情>>
业绩披露：
2023年年报每股收益8.02美元,归母净利润11.61亿美元,同比去年增长-61.89%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益6.30美元,归母净利润9.11亿美元,同比去年增长-63.49%
|
| 2023-08-05 |
复牌提示：
2023-08-04 18:38:03 停牌，复牌日期 2023-08-07 07:10:00
|
| 2023-04-28 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2024 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To hold an advisory vote on executive compensation.
4.To hold an advisory vote on the frequency of the advisory vote on executive compensation.
5.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2023-04-28 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2024 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To hold an advisory vote on executive compensation.
4.To hold an advisory vote on the frequency of the advisory vote on executive compensation.
5.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2022-04-29 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2023 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To hold an advisory vote on executive compensation.
4.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.To elect the 13 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2022 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To hold an advisory vote on executive compensation.
4.To approve an amendment to Biogen’s Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision.
5.To act on a stockholder proposal, if properly presented at the meeting, requesting that Biogen prepare a report on Biogen’s lobbying activities.
6.To act on a stockholder proposal, if properly presented at the meeting, requesting that Biogen prepare a report on Biogen’s gender pay gap.
7.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2020-04-20 |
股东大会：
将于2020-06-03召开股东大会
会议内容 ▼▲
- 1.To elect the 12 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until the 2021 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
3.To hold an advisory vote on executive compensation.
4.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2019-04-30 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.To elect the 14 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until the 2020 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
3.To hold an advisory vote on executive compensation.
4.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2018-04-27 |
股东大会：
将于2018-06-12召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until the 2019 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.To hold an advisory vote on executive compensation.
4.To consider and vote on a stockholder proposal requesting certain proxy access bylaw amendments, if properly presented at the annual meeting.
5.To consider and vote on a stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements, if properly presented at the annual meeting.
6.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2017-04-26 |
股东大会：
将于2017-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the eleven nominees identified in the accompanying proxy statement to our Board of Directors to serve for a one-year term extending until the 2018 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To hold an advisory vote on executive compensation.
4.To hold an advisory vote on the frequency of the advisory vote on executive compensation.
5.To approve the Biogen Inc. 2017 Omnibus Equity Plan.
6.To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
|
| 2016-04-15 |
股东大会：
将于2016-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the eleven nominees identified in this proxy statement to our Board of Directors to serve for a one-year term extending until the 2017 annual meeting of stockholders and their successors are duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
3.To hold an advisory vote on executive compensation.
4.To transact such other business as may be properly brought before the meeting and any adjournments or postponements.
|
| 2015-04-30 |
股东大会：
将于2015-06-10召开股东大会
会议内容 ▼▲
- 1. To elect the eleven nominees identified in this proxy statement to our Board of Directors to serve for a one-year term extending until the 2016 annual meeting of stockholders and their successors are duly elected and qualified.
2. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
3. To hold an advisory vote on executive compensation.
4. To approve our 2015 Employee Stock Purchase Plan.
5. To approve an amendment to our 2006 Non-Employee Directors Equity Plan to extend the term of the plan.
6. To transact such other business as may be properly brought before the meeting and any adjournments or postponements.
|